Severity
Moderate
FDA Drug recall · Reported March 8, 2017
Failed Stability Specifications: confirmed out of specification results obtained during refrigerated material stability testing indicating that drug may settle within drug cassett…
AbbVie Inc. recalled Duopa (carbidopa and levodopa enteral suspension), 4.63 mg/20 mg per mL, 100 mL cassette,… - a moderate-severity action.
Duopa (carbidopa and levodopa enteral suspension), 4.63 mg/20 mg per mL, 100 mL cassette,… was recalled by AbbVie Inc. in March 8, 2017. Reason: Failed Stability Specifications: confirmed out of specification results obtained during refrigerated material…. Check the official notice for the remedy. Verify recall #D-0495-2017 with the FDA Drug before acting.
The recall
AbbVie Inc. issued this moderate-severity FDA Drug recall-Failed Stability Specifications: confirmed out of specification results obtained during refrigerated material….
Sourced from official FDA Drug enforcement records. Verify recall #D-0495-2017 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0495-2017) was formally reported on March 8, 2017, with the manufacturer initiating the action on January 13, 2017. It is classified under Moderate severity (Class II), with a current status of Terminated. AbbVie Inc. is listed as the recalling firm, operating out of North Chicago, IL. Federal records list the affected scope as 4021 cartons, 7 100-mL cassettes each.
The documented reason for this recall is: Failed Stability Specifications: confirmed out of specification results obtained during refrigerated material stability testing indicating that drug may settle within drug cassettes nearing the end of their refrigerated… Distribution data in the federal record shows the product reached: TN and IL. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug and 1 from AbbVie Inc. - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
4021 cartons, 7 100-mL cassettes each
Related Recalls
6
5 from same agency
Duopa (carbidopa and levodopa enteral suspension), 4.63 mg/20 mg per mL, 100 mL cassette, 7 cassettes per carton, Rx Only, AbbVie Inc., North Chicago, IL 60064 --- NDC 0074-3012-07
Failed Stability Specifications: confirmed out of specification results obtained during refrigerated material stability testing indicating that drug may settle within drug cassettes nearing the end of their refrigerated shelf-life
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0495-2017 |
| Date reported | March 8, 2017 |
| Date initiated | January 13, 2017 |
| Recalling firm | AbbVie Inc. |
| Firm location | North Chicago, IL |
| Affected scope | 4021 cartons, 7 100-mL cassettes each |
| Distribution | TN and IL |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported March 8, 2017. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.